Beta-2 glycoprotein I (b2GPI) is the main antigenic target for anti-phospholipid antibodies (aPL), the serological markers of anti-phospholipid syndrome (APS). Conformational changes of the molecule seem to be essential for exposing the cryptic epitope for aPL binding and to trigger pathogenic pathways. There is increasing evidence that a conformational epitope located in the Domain I (DI) of the molecule is the main epitope targeted by human autoantibodies. The pathogenic role of the DI epitope has been recently supported by in vivo models and by immuno-histopathological findings in APS patients. Antibodies targeting b2GPI-DI are more frequently detected in patients with full-blown APS compared to asymptomatic aPL carriers or patients with infectious diseases who have antibodies directed against the whole molecule. Anti-DI antibodies are positively correlated with medium to high titres of aPL, with the presence of lupus anticoagulant and thrombotic and pregnancy manifestations, enabling identification of patients at higher risk of clinical events. However, some APS patients develop antibodies reacting against b2GPI epitopes other than DI, suggesting that other anti-b2GPI antibody subsets may be clinically relevant. Although preliminary results suggest that anti-DI antibodies can be detected by different assays in a comparable manner, further prospective studies are needed to support their use in the clinical setting and their predictive value. Lupus (2016) 25, 905-910.
Background
Anti-phospholipid antibodies (aPL) are the diagnostic laboratory biomarkers for the antiphospholipid syndrome (APS) detectable by three formal diagnostic assays: anti-cardiolipin, antibeta-2 glycoprotein I (b2GPI) and lupus anticoagulant (LA). 1 All these tests detect antibodies directed against different phospholipid-binding proteins; however there is evidence that the most important subpopulations are those reacting with b2GPI and prothrombin (PT). 2, 3 Prothrombin is a PL-binding protein whose biological function is well known, and antibodies against PT have been reported in several studies, but with contrasting results and variable associations with the clinical manifestations of the syndrome. More recently, antibodies against the phosphatidylserine and PT (PS/PT) complex were reported to be a stronger risk factor for arterial and venous thrombosis than antibodies detected on PT alone. Much more controversial remains the association of anti-PT antibodies and aPL-related pregnancy morbidity. 4 Although anti-PT antibodies may mediate some possible pathogenic pathways in vitro, their pathogenic role is still a matter of discussion since there are no sound animal models. 4 On the other hand, while there is sound evidence for the pathogenic role of anti-b2GPI antibodies, the physiological role of the molecule is not clear in spite of the large quantity in normal plasma. 2 The identification of subjects deficient in this protein who were otherwise healthy, as well as the demonstration that b2GPI-deficient mice do not display a clear phenotype, would suggest that the function of b2GPI is not so important in spite of its evolutionary conservation among the species. Despite the observation that deficient humans or animals do not bleed or clot, b2GPI has been reported to display several functions related to haemostasis, at least in in vitro systems: inhibition of ADP-induced platelet aggregation, regulation of contact activation, inhibition of VWF-mediated platelet adhesion/aggregation. The interaction of b2GPI with the specific antibodies has been suggested to affect such functions leading to a pro-thrombotic state. 5 b2GPI can be found in atherosclerotic plaques and binds to oxidized LDL raising the possibility of an active role in atherosclerosis. However, the lack of an accelerated atherosclerosis in primary APS suggests that this is not the case. 6 Moreover, plasmin cleavage of the Lys317-Thr318 bond of b2GPI was reported to display anti-angiogenic activity. 5 b2GPI has been recently found to play a role in innate immunity since the positively charged amino acids located in the Domain V of the molecule can interact with several bacteria, displaying an antibacterial effect. 7 In addition, the molecule was shown to react with lipopolysaccharide (LPS), behaving as a scavenging protein; once bound to LPS the molecule was shown to undergo conformational changes that facilitate the binding of the complex to monocytes that eventually may phagocyte the complex itself. 8 In keeping with such scavenging activity is also the reported binding of b2GPI to apoptotic material. 9 Role of b2GPI in the pathophysiology of APS Antibodies directed against b2GPI have been shown to be pathogenic in APS animal models since they are able to trigger clotting or to increase the size of a preformed thrombus and to increase resorptions in the fetal-loss model. 2, 3, 10 The most widely accepted hypothesis suggests that the antibodies may activate the cells involved in the coagulation cascade (endothelial cells, monocytes, platelets) by recognizing the target molecule present on their cell membrane. 2, 3, 10 b2GPI is predominantly synthesized in hepatocytes and circulates in the blood at variable levels (50-500 mg/ mL); it is generally assumed that the molecule binds to the cells through different receptors (Toll-like (TLR)2,4,6, Annexin A2, GPIba, LRP8) or preferentially interacts with negativecharged structures (such as heparin-sulphate on resting endothelial cells and PS exposed on the membrane of activated platelets). 2 As for the binding to anionic phospholipids, the affinity for these receptors can be increased after b2GPI dimerization or its complexing with the antibodies; both events ultimately would stabilize the binding and allow intracellular signalling. 10 Upon engagement of b2GPI receptors on target cells, anti-b2GPI antibody binding results in the activation of intracellular mediators such as nuclear factor kappa B (NF-kB) and p38 mitogen-activated protein kinase (p38MAPK). Recently, a multiprotein complex including TLR4 and Annexin A2 was suggested to be involved in anti-b2GPI antibodymediated signalling both in monocytes and in endothelial cells. The composition of the complex appears to be different depending on the cell type, since it consists of Annexin A2, TLR4, calreticulin, and nucleolin in endothelial cells, while NF-kB translocation in monocytes is engaged through a clathrin-dependent endocytic pathway, a mechanism that requires CD14 (TLR4 co-receptor) and Annexin A2. 10 The phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been recently identified as an additional signalling cascade engaged by aPL that recruits the mammalian target of rapamycin (mTOR), a kinase modulating cellular growth, proliferation and apoptosis. 10 Some of these candidate receptors for b2GPI have been investigated in animal models and a critical role has been confirmed for TLRs, Annexin A2 and LRP8. However, animals deficient in each of these molecules are protected from the thrombogenic effect of aPL only in part, suggesting that none of the receptors is essential and that all are semi-redundant. 2 b2GPI and the endothelium in APS According to the above-mentioned findings, endothelial b2GPI has been supposed to represent the most important antigenic target for anti-b2GPI antibodies because of the major role of endothelium on coagulation. This would suggest that b2GPI could be present on the vessel walls consistent with the finding that the molecule can be detectable on the endothelial cell membrane in vitro. However, this does not seem to be the case, since b2GPI cannot be found on human vascularized tissues by indirect immunofluorescence using a monoclonal anti-human b2GPI (Meroni, unpublished observation). This is supported by data showing that passively infused exogenous labelled b2GPI cannot be found on vascular tissues in living animals. 11 Such a finding is not surprising since a persistent and significant endothelial expression of the antigen would justify a continuous clotting, in anti-b2GPI antibodies PL Meroni conflict with the evidence that thrombotic events take place only occasionally and the persistent presence of the autoantibodies. According to the ''two hit theory'', it has been suggested that the inflammatory second hit may affect b2GPI expression on the endothelium. 2 Actually, animal pre-treatment with small amount of LPS increases the presence of injected labelled b2GPI in vascular tissues and eventually allows antibody binding and complement fixation. 11 In vitro studies seem to suggest that this result can be at least in part related to the enhanced membrane expression of TLRs and ultimately to an increased presence of the molecule on the cell surface. 12 We recently described a case report that apparently also supports such a cascade of events in patients. In fact, b2GPI could be demonstrated by indirect immunofluorescence staining on the wall of a popliteal artery after thrombosis in a primary APS patient at variance with the negative staining in normal arterial vessels. More importantly, it colocalized with IgG and complement deposits. We hypothesize that a local inflammatory insult can be responsible for the increased b2GPI presence on the vessel wall, followed by antibody binding in an amount large enough to trigger complement activation and clotting. 13 b2GPI and the placenta in APS Pregnancy complications in APS are also associated with the persistence presence of b2GPIdependent aPL and their pathogenic role has been supported by sound evidence from in vitro and in vivo models. 2, 10 Placental thrombosis does not explain all miscarriages and alternative (or additive) mechanisms have been described. All of them involve the effect of b2GPI-dependent aPL antibodies on uterine endothelial cells, trophoblast and/or decidual cells, eventually leading to a defective placentation. 2, 14 The observation that passive infusion of b2GPI-dependent IgG from APS sera is able to increase fetal loss and growth restriction in pregnant mice without requiring a second hit at variance with the thrombosis model. b2GPI can be demonstrated on trophoblast and decidual cell monolayers in vitro in a manner similar to that reported for endothelial cultures, while different results have been reported for its presence in tissues in vivo. In fact, the molecule can be detectable on the surface of placental syncytium-trophoblast in normal human placenta sections. In addition, the infusion of labelled b2GPI allows staining on trophoblast and uterine endothelium in contrast with the lack of staining in other vascularized tissues in naive animals. 2, 11 This could make placenta different from other tissues because of such increased presence of the target antigen. Local modification (i.e. via hormones) may represent further variables that could explain why the second hit is not apparently needed suggesting that the pregnancy itself may behave as the second hit. 4 The finding that b2GPI knock-out mice display reduced fertility fits well with a key -but still undefinedphysiological role of the molecule at the level of the female reproductive system and may account for its local presence. 15 Still open is the question why there are patients with apparently similar anti-b2GPI antibodies that display vascular or obstetrical manifestations only. An elegant hypothesis suggests that the IgG fractions from patients with vascular, but not those with obstetrical, events can affect different cell signalling pathways; thus explaining why in one case they are responsible for clotting but not for miscarriages and vice versa. 16 However, there is no evidence at the moment that these antibody subpopulations can be characterized by a different antigenic profile.
Altogether these data strongly support the diagnostic power of b2GPI-dependent aPL from a pathogenic point of view and reinforce their routine use as laboratory classification/diagnostic criteria.
Epitope specificity of anti-b2GPI antibodies: the new aspect
There is evidence that the humoral immune response against b2GPI can be directed against epitopes located in different domains of the molecule. Accordingly, antibodies against peptides representing fragments of the domains have been described. 17 Using domains-deletion mutants showed that DI displays the immunodominant epitope. 18 The attempt to correlate the presence of antibodies against the different epitopes with peculiar clinical phenotypes did not succeed in the past. 17 It has been suggested that the use of linear peptides was the reason for such a failure, owing to the fact that B-cell autoimmunity is supposed to be mainly against conformational epitopes. Accordingly, it has been found that b2GPI coated on hydrophilic, but not hydrophobic, microtiter plates displays conformational changes that expose DI to the surface, making it more accessible for autoantibody binding. The reactivity against DI was associated anti-b2GPI antibodies PL Meroni with the full-blown APS clinical picture and specifically with the positivity for LA, suggesting a higher diagnostic/prognostic value for these aPL. 19, 20 The main DI epitope was reported to involve arginine 39-arginine 43, aspartic acid 8-aspartic acid 9, and possibly the interlinking region between DI and DII, with R39 being the most important residue. 21, 22 The epitope in the circular and the S-shape forms of the molecule is not available for autoantibody binding but can be exposed in the open J configuration. It is not available to the antibodies in the circular and the S-shape forms of the molecule, but can be exposed in the open J configuration. Upon b2GPI binding to anionic structures, antibodies or LPS, the molecule opens up to a J configuration, so exposing the critical epitope arginine 39-arginine 43 that in turn becomes available for antibody binding. 5, 22 The conformationaldependent binding of anti-b2GPI antibodies to DI might explain why b2GPI/anti-b2GPI immune complexes are not easily detected in APS sera because the epitope is covered by the interaction between DI and DV in the circular form of the molecule that represents the main variant present in the circulation.
The conformational peptide was used to detect specific antibodies and the results were comparable with those obtained by using a solidphase assay coated with the whole DI molecule. 22 Interestingly, an scFv human monoclonal anti-b2GPI antibody was shown to react with both the peptide and the whole DI. 23 This monoclonal was pathogenic in animal models of aPL-related thrombosis and fetal loss, so offering the direct demonstration of the pathogenicity of anti-DI antibodies. By immunohistochemistry, the same monoclonal was also able to stain b2GPI on the vessel wall of a popliteal artery biopsy affected by thrombosis from an APS patient and to detect labelled b2GPI in the vascular tissues after its passive infusion in LPS-treated animals. 11, 13 This finding further supports the fact that the epitope is available in vivo and specifically in the vessels. It should be underlined that both in the arterial specimen from the patient and in the infused LPS-treated animals, a second hit already took place, suggesting that it could have modified the conformation of the molecule making DI available to the antibodies. Preliminary data suggest that IgG fractions or whole sera from APS patients positive for anti-DI can be pathogenic in animal models of thrombosis and fetal loss (Meroni et al., unpublished observations). The last finding is in line with the reported ability of the DI conformational peptide to protect, at least in part, mice from the thrombogenic effect of passively infused human IgG aPL, likely by inhibiting the antibody binding to the target molecule. 24 Whether or not anti-DI antibodies are the only thrombogenic aPL subpopulation should be confirmed in further studies.
The detection of anti-DI antibodies mainly in patients with medium-high titres of aPL and/or double-triple positivities in the diagnostic assays further supports the suggestion that DI does represent the immunodominant epitope of the molecule. [25] [26] [27] [28] [29] [30] [31] Subsequent studies documented that anti-DI autoantibodies, being much less frequent in control populations in which antibodies against the whole molecule can be detected, provide good specificity for APS or systemic autoimmune conditions. 32, 33 The opposite seems to be true for IgG antibodies against DIV-V, which are more frequent in asymptomatic aPL carriers, in patients with leprosy, in children suffering from atopic dermatitis or born from mothers affected by systemic autoimmune disorders. This finding prompted us to suggest that anti-DI antibodies cluster in patients with autoimmune diseases and that the ratio between antibodies targeting DI and those targeting DIV-V may be useful in discriminating among anti-b2GPI antibodies those that are really autoimmune from those that are a mere epiphenomenon occurring in non-immune conditions and with no pathogenic role. 32, 33 Anti-DI antibodies have been associated with both arterial and venous thrombosis with a significant increase in the odds ratio for these events. [25] [26] [27] [30] [31] [32] However, the fact that the antibodies are usually detectable in patients double or triple positive for the APS laboratory classification tests and their strong association with LA positivity raise the issue whether the predictive power is dependent on this antibody subpopulation itself or simply on their presence in patients with high risk aPL profiles. Anti-DI antibodies have also been described in obstetric APS patients (even in pure obstetric patients without vascular events), although with lower prevalence and in some reports with lower titres. 22 Further prospective studies, including the right control groups, are needed to confirm the predictive value of anti-DI antibodies.
Anti-DI antibodies are much more frequent in APS patients or in patients with systemic autoimmune conditions than in subjects/patients in whom the positivity for aPL can be related to transient synthesis or to polyclonal B-cell activation associated to infections or other conditions. This observation together with the association with high risk aPL profiles strongly suggest that anti-DI antibodies may be a useful tool to selectively anti-b2GPI antibodies PL Meroni identify true APS patients and among them those at highest risk for the clinical manifestations. The same could also be true for stratifying the risk in aPL asymptomatic carriers. However, ad hoc prospective studies need to be carried out before drawing definite conclusions. 22, 32, 33 In spite of the higher specificity, the anti-DI assay apparently displays a lower sensitivity in comparison to the assay detecting antibodies against the whole molecule. In fact, depending on the cut-off, up to 20% of all medium-high titre anti-b2GPI positive sera do not react with DI, reducing the possibility of substituting the standard test with a DI specific test. 33 However, since the sensitivity of an immunoassay always depends on the selected cut-off, lower cut-off values for anti-DI antibodies might yield similar assay performance compared to assays based on the whole molecule, as demonstrated in an international multi-site study. 31 Conclusions b2GPI is a pleiotropic molecule that behaves as the main target antigen for aPL, especially in vascular tissues after conformational modification. The evidence that antibodies reacting with the molecule play a key pathogenic role in vascular and obstetric APS strongly supports the diagnostic and prognostic value of these autoantibodies in the laboratory tests.
DI is the most relevant epitope targeted by anti-b2GPI antibodies in patients with autoimmune conditions. Anti-DI antibodies have been consistently revealed to be clinically interesting, being significantly associated with both vascular and obstetric aPL-related events.
Despite some corroborating findings, it is far too soon to recommend replacement of anti-b2GPI antibody testing with an anti-DI antibody assay. Tests for anti-DI antibodies display lower sensitivity for APS at cut-off values yielding high specificity. Indeed, a low percentage of anti-b2GPI-antibodypositive patients with a full blown diagnosis of APS display autoantibodies reacting with b2GPI epitopes other than DI. These subjects could be misdiagnosed if testing for antibodies against the whole b2GPI was not available.
Anti-DI antibodies are significantly associated with APS clinical events and with a high-risk aPL profile, but there is still no definite prospective evidence that the assay may provide a stronger predictive value for aPL-related manifestations than antibodies against the whole molecule. However, anti-DI antibodies can offer more information on aPL autoimmune nature and a straightforward risk-stratification as a second level test for APS.
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